263 related articles for article (PubMed ID: 20011994)
21. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
Dejas-Eckertz P; Schäffner G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
[TBL] [Abstract][Full Text] [Related]
22. Clinical development of gene therapy needs a tailored approach: a regulatory perspective from the European Union.
Narayanan G; Cossu G; Galli MC; Flory E; Ovelgonne H; Salmikangas P; Schneider CK; Trouvin JH
Hum Gene Ther Clin Dev; 2014 Mar; 25(1):1-6. PubMed ID: 24649836
[TBL] [Abstract][Full Text] [Related]
23. GMP facilities for manufacturing of advanced therapy medicinal products for clinical trials: an overview for clinical researchers.
Alici E; Blomberg P
Curr Gene Ther; 2010 Dec; 10(6):508-15. PubMed ID: 21054243
[TBL] [Abstract][Full Text] [Related]
24. European Medicines Agency, CAT Secretariat & US Food and Drug Administration.
Regen Med; 2011 Nov; 6(6 Suppl):90-6. PubMed ID: 21999268
[TBL] [Abstract][Full Text] [Related]
25. Access to advanced therapy medicinal products in the EU: where do we stand?
Mahalatchimy A
Eur J Health Law; 2011 May; 18(3):305-17. PubMed ID: 21870592
[TBL] [Abstract][Full Text] [Related]
26. [The Innovation Office of the Paul-Ehrlich-Institut. Regulatory support during the scientific development of ATMP].
Ziegele B; Dahl L; Müller AT
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):857-66. PubMed ID: 21698540
[TBL] [Abstract][Full Text] [Related]
27. [The certification of advanced therapy medicinal products. A quality label for product development in small and medium-sized enterprises].
Berger A; Schüle S; Flory E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):816-21. PubMed ID: 21698534
[TBL] [Abstract][Full Text] [Related]
28. [Approval of clinical trials of immunobiological medicinal products at the Paul Ehrlich Institute].
Krafft H; Cichutek K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):168-72. PubMed ID: 15726457
[TBL] [Abstract][Full Text] [Related]
29. The advanced therapy classification procedure. Overview of experience gained so far.
Voltz-Girolt C; Celis P; Boucaumont M; D'Apote L; Pinheiro MH; Papaluca-Amati M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):811-5. PubMed ID: 21698533
[TBL] [Abstract][Full Text] [Related]
30. Regulatory framework of immunologicals in the European Union.
Sauer F
Biologicals; 1994 Dec; 22(4):307-11. PubMed ID: 7779353
[No Abstract] [Full Text] [Related]
31. Informed consent and living human cells.
Maloney DM
Hum Res Rep; 2002 Jul; 17(7):3. PubMed ID: 12731490
[No Abstract] [Full Text] [Related]
32. [A comprehensive assessment of ATMP. Difficulties and approaches].
Thanner M; Nagel E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):843-8. PubMed ID: 21698538
[TBL] [Abstract][Full Text] [Related]
33. [The authorization of clinical trials by the federal authorities].
Schriever J; Schwarz G; Steffen C; Krafft H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Apr; 52(4):377-86. PubMed ID: 19266174
[TBL] [Abstract][Full Text] [Related]
34. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.
Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M
Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839
[TBL] [Abstract][Full Text] [Related]
35. Regulation of cellular therapy in Australia.
Trickett AE; Wall DM
Pathology; 2011 Oct; 43(6):627-34. PubMed ID: 21897330
[TBL] [Abstract][Full Text] [Related]
36. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
Lucas-Samuel S; Ferry N; Trouvin JH
Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
[TBL] [Abstract][Full Text] [Related]
37. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
[TBL] [Abstract][Full Text] [Related]
38. [Risk-benefit evaluation of medicinal products. An element of Health Technology Assessment].
Hart D
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):204-14. PubMed ID: 15726462
[TBL] [Abstract][Full Text] [Related]
39. [Strategic considerations on the design and choice of animal models for non-clinical investigations of cell-based medicinal products].
Lehmann J; Schulz RM; Sanzenbacher R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1215-24. PubMed ID: 26431722
[TBL] [Abstract][Full Text] [Related]
40. [Safety monitoring of cell-based medicinal products (CBMPs)].
Funk MB; Frech M; Spranger R; Keller-Stanislawski B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1239-46. PubMed ID: 26391098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
